MANAGED ENTRY AGREEMENTS: PORTUGUESE EXPERIENCE

被引：0
|
作者：
Goncalves, L. [1 ]
Teixeira, M. [1 ]
Caldeira, S. [1 ]
Ramos, R. [1 ]
机构：
[1] INFARMED LP, Lisbon, Portugal
来源：
VALUE IN HEALTH | 2016年 / 19卷 / 07期
关键词：
D O I：
10.1016/j.jval.2016.09.890
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PHP341
引用
收藏
页码：A500 / A500
页数：1
相关论文
共 50 条
  • [21] Integrative Review of Managed Entry Agreements: Chances and Limitations
    Dias, Carolina Zampirolli
    Godman, Brian
    Gargano, Ludmila Peres
    Azevedo, Pamela Santos
    Garcia, Marina Morgado
    Cazarim, Maurilio Souza
    Neiva Pantuzza, Lais Lessa
    Ribeiro-Junior, Nelio Gomes
    Pereira, Andre Luiz
    Borin, Marcus Carvalho
    Zuppo, Isabella de Figueiredo
    Iunes, Roberto
    Pippo, Tomas
    Hauegen, Renata Curi
    Vassalo, Carlos
    Laba, Tracey-Lea
    Simoens, Steven
    Marquez, Sergio
    Gomez, Carolina
    Voncina, Luka
    Selke, Gisbert W.
    Garattini, Livio
    Kwon, Hye-Young
    Gulbinovic, Jolanta
    Lipinska, Aneta
    Pomorski, Maciej
    McClure, Lindsay
    Furst, Jurij
    Gambogi, Rosana
    Ortiz, Carla Hernandez
    Canuto Santos, Vania Cristina
    Araujo, Denizar Vianna
    Araujo, Vania Eloisa
    Acurcio, Francisco de Assis
    Alvares-Teodoro, Juliana
    Guerra-Junior, Augusto Afonso
    PHARMACOECONOMICS, 2020, 38 (11) : 1165 - 1185
  • [22] Financial Outcomes of Managed Entry Agreements for Pharmaceuticals in Italy
    Trotta, Francesco
    Guerrizio, Maria Alessandra
    Di Filippo, Aurora
    Cangini, Agnese
    JAMA HEALTH FORUM, 2023, 4 (12): : E234611
  • [23] MANAGED-ENTRY AGREEMENTS: POSSIBLE OPTIONS FOR VACCINES?
    Baron-Papillon, F.
    Easley, C.
    Saint Sardos, C.
    Lucas, F.
    VALUE IN HEALTH, 2014, 17 (07) : A686 - A686
  • [24] THE OUTCOMES OF MANAGED ENTRY AGREEMENTS IN ROMANIA FROM 2015 TO 2022
    Radu, Ciprian paul
    Dragoi, Loredana
    Udroiu, Mihnea a.
    Pana, Bogdan c.
    Iliescu, Mihaela catrinel
    FARMACIA, 2023, 71 (06) : 1316 - 1323
  • [25] PAYER VS. INDUSTRY VIEWS ON MANAGED ENTRY AGREEMENTS
    Lucas, F.
    Wong, I
    VALUE IN HEALTH, 2015, 18 (07) : A568 - A569
  • [26] USING CLAIMS DATA FOR EVIDENCE GENERATION IN MANAGED ENTRY AGREEMENTS
    Brandes, Alina
    Schwarzkopf, Larissa
    Rogowski, Wolf H.
    INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE, 2016, 32 (1-2) : 69 - 77
  • [27] THE IMPACT OF MANAGED ENTRY AGREEMENTS ON DRUG TIME TO MARKET IN ITALY
    Urbinati, D.
    Rova, A.
    Mantuano, M.
    VALUE IN HEALTH, 2017, 20 (09) : A703 - A703
  • [28] MANAGED ENTRY AGREEMENTS IN EGYPT: CURRENT PRACTICES AND FUTURE PREFERENCES
    Fasseeh, A. N.
    Adel, R.
    Elezbawy, B.
    Abouelmaged, E.
    Abaza, S.
    Kalo, Z.
    VALUE IN HEALTH, 2020, 23 : S652 - S653
  • [29] Introduction of managed entry agreements in Korea: Problem, policy, and politics
    Kim, Hyungmin
    Godman, Brian
    Kwon, Hye-Young
    Hong, Song Hee
    FRONTIERS IN PHARMACOLOGY, 2023, 14
  • [30] SUCCESS AND FAILURE OF STRAIGHTFORWARD VERSUS SOPHISTICATED MANAGED ENTRY AGREEMENTS
    Van de Vijver, I
    Quanten, A.
    Knappenberg, V
    De Ridder, R.
    VALUE IN HEALTH, 2016, 19 (07) : A499 - A499
12345